Assessment of long‐term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy

Merdan, Selin; Tomlins, Scott A.; Barnett, Christine; Morgan, Todd M.; Montie, James E.; Wei, John T.; Denton, Brian T.

doi:10.1002/cncr.29611

Cited by 31 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In solid tumors, recurrent gene fusions have been described in prostate cancer ( TMPRSS2-ERG ), lung cancer ( EML4-ALK ), and secretory breast cancer ( ETV6-NTRK3 ) [ 5 – 7 ]. TMPRSS2-ERG has been reported in >50% of tumors, and has been used to stratify patients according to risk [ 8 ] and survival time [ 9 ]. These examples demonstrate that recurrent gene fusions have the potential for clinical benefit as drug targets and may have diagnostic and prognostic uses.…”

Section: Introductionmentioning

confidence: 99%

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes

Earp

Rama

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Gene fusions play a critical role in some cancers and can serve as important clinical targets. In epithelial ovarian cancer (EOC), the contribution of fusions, especially by histological type, is unclear. We therefore screened for recurrent fusions in a histologically diverse panel of 220 EOCs using RNA sequencing. The Pipeline for RNA-Sequencing Data Analysis (PRADA) was used to identify fusions and allow for comparison with The Cancer Genome Atlas (TCGA) tumors. Associations between fusions and clinical prognosis were evaluated using Cox proportional hazards regression models. Nine recurrent fusions, defined as occurring in two or more tumors, were observed. CRHR1-KANSL1 was the most frequently identified fusion, identified in 6 tumors (2.7% of all tumors). This fusion was not associated with survival; other recurrent fusions were too rare to warrant survival analyses. One recurrent in-frame fusion, UBAP1-TGM7, was unique to clear cell (CC) EOC tumors (in 10%, or 2 of 20 CC tumors). We found some evidence that CC tumors harbor more fusions on average than any other EOC histological type, including high-grade serous (HGS) tumors. CC tumors harbored a mean of 7.4 fusions (standard deviation [sd] = 7.4, N = 20), compared to HGS EOC tumors mean of 2.0 fusions (sd = 3.3, N = 141). Few fusion genes were detected in endometrioid tumors (mean = 0.24, sd = 0.74, N = 55) or mucinous tumors (mean = 0.25, sd = 0.5, N = 4) tumors. To conclude, we identify one fusion at 10% frequency in the CC EOC subtype, but find little evidence for common (> 5% frequency) recurrent fusion genes in EOC overall, or in HGS subtype-specific EOC tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes

Earp

Rama

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…A urine test to detect PCA3 for noninvasive PCa diagnosis outperforms prostate-specific antigen in specific clinical settings. 23 A commercial PCa prognostic signature Decipher includes several noncoding transcripts. 24 Metastasis associated in lung adenocarcinoma transcript 1-derived mini-RNA was found to improve diagnostic accuracy for predicting the results of prostate biopsy.…”

Section: Discussionmentioning

confidence: 99%

The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA

Shi

Zhang

Nian

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) promote cell proliferation, migration, invasion and castration resistance in prostate cancer (PCa). Understanding the inherited molecular mechanisms by which lncRNAs contribute to the progression of PCa to a lethal disease could have an important impact on cancer detection, diagnosis and prognosis. In our study, PCa‐associated lncRNA transcripts from RNA‐seq data were identified and screened via bioinformatics analysis, NCBI annotations and literature review. We identified a novel lncRNA, lncAPP (lncRNA activated in PCa progression), which activates in PCa progression and is expressed in primary tumor tissues and urine samples of patients with localized or advanced PCa. Urinary‐based lncAPP is a promising biomarker for predicting PCa progression. In vitro and in vivo studies demonstrated that lncAPP enhanced cell proliferation and promoted migration and invasion. The underlying mechanism of lncRNA was investigated by RNA immunoprecipitation, dual‐luciferase reporter system assay, etc. Upregulation of lncAPP promoted cell migration and invasion via competitively binding miR218 to facilitate ZEB2/CDH2 expression. In addition, in vivo subcutaneous tumor xenograft models and tail intravenously injection metastatic models were constructed to evaluate lncRNA function. Targeting lncAPP/miR218 axis in cell lines and tumor xenografts restrained tumor progression properties both in vitro and in vivo. These results establish that lncAPP/miR218 axis plays a critical role in PCa progression, and they also suggest new strategies to prevent tumor progression for therapeutic purposes.

show abstract

“…into a urine test is significantly higher than that of the PSA test (Mikhaĭlenko et al 2014). This combination can also reduce more than half of repeat biopsies with no notable negative consequences suggesting that a large number of men could avoid unnecessary invasive procedures by applying this approach (Merdan et al 2015).…”

Section: Gene Fusion Biomarkersmentioning

confidence: 97%

Revisiting Prostate Cancer in India: A Genomic View<strong> </strong><strong> </strong>

Perera¹,

Gupta²,

Shukla³

et al. 2019

Preprint

View full text Add to dashboard Cite

In the recent past, there has been a rise in Prostate Cancer (PCa) in Asia, particularly India.  Although systematic reviews on PCa have dealt on the genetics, genomics and the environmental influence in causal of PCa, no predictive analytics in comparing the PCa from Caucasian, American to Asian population was attempted. In this review article, we have attempted to elaborate this aspect of PCa and deliberated on challenges related to next generation sequencing methods of PCa’s manifestation when compared to the west.

show abstract

Assessment of long‐term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy

Cited by 31 publications

References 52 publications

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes

The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA

Revisiting Prostate Cancer in India: A Genomic View<strong> </strong><strong> </strong>

Contact Info

Product

Resources

About